Skip to main content
. 2021 Dec 3;5:CCI.21.00013. doi: 10.1200/CCI.21.00013

FIG 2.

FIG 2.

Comparison of median rwOS (with 95% CI) in CAS with six US data sets in patients with aNSCLC treated with PD-(L)1 inhibitors. aNSCLC, advanced non–small-cell lung cancer; CAS, Cancer Analysis System; OS, overall survival; PD-(L)1, programmed death-1 or programmed death ligand-1; rwOS, real-world overall survival.